Comparison of Hemophagocytic Lymphohistiocytosis Diagnostic Criteria in Malignancy-Associated Hemophagocytic Lymphohistiocytosis Patients

H. Kırkızlar, Tuğcan ALP KIRKIZLAR, U. Demirci, Sedanur Karaman Gulsaran, V. Bas, E. Umit, A. Demir
{"title":"Comparison of Hemophagocytic Lymphohistiocytosis Diagnostic Criteria in Malignancy-Associated Hemophagocytic Lymphohistiocytosis Patients","authors":"H. Kırkızlar, Tuğcan ALP KIRKIZLAR, U. Demirci, Sedanur Karaman Gulsaran, V. Bas, E. Umit, A. Demir","doi":"10.46310/tjim.1121064","DOIUrl":null,"url":null,"abstract":"Background Fulfilling diagnostic criteria of hemophagocytic lymphohistiocytosis (HLH) is challenging due to unavailable laboratory tests. Hence, we aimed to reveal malignancy-associated-HLH (M-HLH) patients in our center, which can not be reached in all tests. \nMaterial and Methods Nine patients with M-HLH were analyzed retrospectively. \nResults The median age was 59 years. The distribution of the underlying diseases was like diffuse large B cell lymphoma in 3 patients, acute myeloid leukemia in 2 patients, Hodgkin lymphoma in 2 patients, T cell non-Hodgkin lymphoma in 1 patient, and small cell lung cancer in 1 patient. According to HLH-2004 diagnostic criteria except for soluble CD25 and natural killer activity tests; one patient had 3/6, six patients had 5/6, two patients had 6/6 criteria while the median H-score was 258 at diagnosis. According to Tamamyan et al’s criteria; at the diagnosis, all patients had ≥7 (between 7-12) of 18 parameters. Patients fulfilled ≥5 parameters a median of 15 days (3-52 days) before the diagnosis and on that time six patients had 3/6 criteria of HLH-2004. 88.8% of the patients died. The median duration of survival was 8.5 days (1-18 days). \nConclusions Unavailability of the tests in some countries and centers as in ours results in complications to fulfill 5 of 8 criteria and being delayed in diagnosis and treatment. We need to develop more specific and accessible criteria, and grading systems for M-HLH diagnose.","PeriodicalId":23372,"journal":{"name":"Turkish Journal of Internal Medicine","volume":"2016 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Internal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46310/tjim.1121064","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background Fulfilling diagnostic criteria of hemophagocytic lymphohistiocytosis (HLH) is challenging due to unavailable laboratory tests. Hence, we aimed to reveal malignancy-associated-HLH (M-HLH) patients in our center, which can not be reached in all tests. Material and Methods Nine patients with M-HLH were analyzed retrospectively. Results The median age was 59 years. The distribution of the underlying diseases was like diffuse large B cell lymphoma in 3 patients, acute myeloid leukemia in 2 patients, Hodgkin lymphoma in 2 patients, T cell non-Hodgkin lymphoma in 1 patient, and small cell lung cancer in 1 patient. According to HLH-2004 diagnostic criteria except for soluble CD25 and natural killer activity tests; one patient had 3/6, six patients had 5/6, two patients had 6/6 criteria while the median H-score was 258 at diagnosis. According to Tamamyan et al’s criteria; at the diagnosis, all patients had ≥7 (between 7-12) of 18 parameters. Patients fulfilled ≥5 parameters a median of 15 days (3-52 days) before the diagnosis and on that time six patients had 3/6 criteria of HLH-2004. 88.8% of the patients died. The median duration of survival was 8.5 days (1-18 days). Conclusions Unavailability of the tests in some countries and centers as in ours results in complications to fulfill 5 of 8 criteria and being delayed in diagnosis and treatment. We need to develop more specific and accessible criteria, and grading systems for M-HLH diagnose.
恶性肿瘤相关噬血细胞淋巴组织细胞增多症诊断标准的比较
背景:由于缺乏实验室检测,满足噬血细胞性淋巴组织细胞增多症(HLH)的诊断标准具有挑战性。因此,我们的目标是在我们的中心发现恶性肿瘤相关的hlh (M-HLH)患者,这在所有的测试中都无法达到。材料与方法对9例M-HLH患者进行回顾性分析。结果中位年龄59岁。基础疾病分布为弥漫性大B细胞淋巴瘤3例,急性髓系白血病2例,霍奇金淋巴瘤2例,T细胞非霍奇金淋巴瘤1例,小细胞肺癌1例。除可溶性CD25和自然杀伤活性试验外,均符合HLH-2004诊断标准;1例为3/6,6例为5/6,2例为6/6,诊断时h评分中位数为258。根据Tamamyan等人的标准;诊断时,所有患者在18项参数中均≥7项(7-12之间)。患者在诊断前15天(3-52天)满足≥5个参数,其中6例患者达到HLH-2004标准的3/6。88.8%的患者死亡。中位生存期为8.5天(1-18天)。结论:在一些国家和中心,如我国,无法提供检测,导致无法满足8项标准中的5项的并发症,并延误了诊断和治疗。我们需要为M-HLH的诊断制定更具体和更容易获得的标准和分级系统。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信